Prostate cancer expert, Matthew R. Smith, MD, PhD, shares his thoughts about importance of testing in treatment of metastatic castration-resistant prostate cancer (mCRPC).
Matthew R. Smith, MD, PhD: The patient had reported no family history of prostate cancer, but that's a relatively insensitive predictor of having an inherited alteration in a cancer susceptibility gene. The lack of a family history would not discourage me from recommending both germline and tumor genetic testing in this patient. We offer germline genetic testing to all patients with recurrent or de novo metastatic disease and specific younger individuals with high-risk localized disease for the purpose of looking for either DNA repair defects or mismatch repair. Identification of either of those alterations could inform subsequent treatment decisions. For patients who do not have germline alterations or did not have prior germline testing, we'd also recommend tumor genetic testing. We typically recommend that at progression, despite first-line treatment for mCRPC because that's the first point at which that information would currently be actionable. For patients who have an identified pathogenic mutation in a DNA repair gene, whether germline or somatic, they may be candidates for a PARP inhibitor either after an androgen receptor pathway inhibitor or after an androgen receptor inhibitor and docetaxel. The prevalence of those mutations is approximately 10% of mismatch repair alterations. MSI [microsatellite instability]high is less common at about 1% to 3%. In the rare patient who has those alterations, we would consider treatment with pembrolizumab.
Transcript edited for clarity.
Case: A 82-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer
Sept. 2016
Initial presentation
Clinical workup
Treatment
April 2018
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
Dehumanizing Language is a Top Culprit in Prostate Cancer Research
February 7th 2024In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the findings from her analysis of the Language of Respect guidelines adopted by the American Society of Clinical Oncology and how well they are followed in prostate cancer abstracts.
Read More
Significance of Early Genetic Testing in HRR-Mutated mCRPC Highlighted by Real-World Observations
January 26th 2024Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.
Read More